Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries.
They do clinical trials for new drugs, including a recent trial for a neutralizing antibody for SARS-CoV-2 for the treatment and prevention of COV19.
With earnings surprises the last two quarters and a Zacks estimate for a strong Q4, Medpace is on track to make a new all-time high.
As it approaches the all-time high, volatility is decreasing while volume is shrinking. There is not much selling going on, so a little demand will cause this to pop above the all-time high and accelerate from there.
Buy point is at 144.49 with a stop loss of 7.63% based on the 10d ATR (x2.7). Position size of R13.1.
Buy Point: 144.49
Stop Loss: 133.47
Position Size: R13.1
They do clinical trials for new drugs, including a recent trial for a neutralizing antibody for SARS-CoV-2 for the treatment and prevention of COV19.
With earnings surprises the last two quarters and a Zacks estimate for a strong Q4, Medpace is on track to make a new all-time high.
As it approaches the all-time high, volatility is decreasing while volume is shrinking. There is not much selling going on, so a little demand will cause this to pop above the all-time high and accelerate from there.
Buy point is at 144.49 with a stop loss of 7.63% based on the 10d ATR (x2.7). Position size of R13.1.
Buy Point: 144.49
Stop Loss: 133.47
Position Size: R13.1